Vladimir Vexler - 31 Mar 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Scientific Officer
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Vladimir Vexler
Issuer symbol
CHRS
Transactions as of
31 Mar 2023
Net transactions value
-$111,342
Form type
4
Filing time
04 Apr 2023, 21:02:33 UTC
Previous filing
24 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Tax liability $111,342 -16,278 -12% $6.84 116,361 31 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Vladimir Vexler is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.
F2 Includes 1,316 shares acquired on May 13, 2022, pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan.